Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47778
Title: Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency?
Authors: Erbaş, İbrahim Mert
Altıncık, Selda Ayça
Çatlı, Gönül
Ünüvar, Tolga
Özhan, Bayram
Abacı, Ahmet
Anik A.
Keywords: Magnesium
Magnesuria
Mineralocorticoids
Pediatrics
Primary adrenal insufficiency
aldosterone
alkaline phosphatase
calcium
chloride
corticotropin
creatinine
fludrocortisone
magnesium
parathyroid hormone
phosphorus
potassium
renin
thyrotropin
vitamin D
fludrocortisone
magnesium
mineralocorticoid
adolescent
adrenal insufficiency
adult
Article
child
clinical article
congenital adrenal hyperplasia
drug megadose
female
human
hypomagnesemia
infant
male
plasma renin activity
retrospective study
salt wasting
urinalysis
blood
clinical trial
congenital adrenal hyperplasia
drug effect
drug monitoring
ion transport
magnesium deficiency
multicenter study
procedures
risk assessment
treatment outcome
urinary excretion
urine
Adrenal Hyperplasia, Congenital
Child
Drug Monitoring
Female
Fludrocortisone
Humans
Ion Transport
Magnesium
Magnesium Deficiency
Male
Mineralocorticoids
Renal Elimination
Retrospective Studies
Risk Assessment
Treatment Outcome
Publisher: Turkiye Klinikleri
Abstract: Background/aim: Aldosterone is a mineralocorticoid that secreted from adrenal glands and a known factor to increase magnesium excretion by direct and indirect effects on renal tubular cells. Although the frequency of hypomagnesemia was found to be approximately 5% in adult studies, there is no study in the literature investigating the frequency of hypomagnesemia in children by using fludrocortisone, which has a mineralocorticoid activity. Materials and methods: A multi-center retrospective study was conducted, including children who were under fludrocortisone treatment for primary adrenal insufficiency and applied to participant pediatric endocrinology outpatient clinics. Results: Forty-three patients (58.1% male, 41.9% prepubertal) included in the study, whose median age was 9.18 (0.61-19) years, and the most common diagnosis among the patients was a salt-wasting form of congenital adrenal hyperplasia (67.4%). Mean serum magnesium level was 2.05 (±0.13) mg/dL, and hypomagnesemia was not observed in any of the patients treated with fludrocortisone. None of the patients had increased urinary excretion of magnesium. Conclusion: Unlike the studies performed in adults, we could not find any evidence of magnesium wasting effect of fludrocortisone treatment with normal or even high doses in children and adolescents. © TÜBİTAK.
URI: https://doi.org/10.3906/sag-2008-167
https://search.trdizin.gov.tr/yayin/detay/485212
https://hdl.handle.net/11499/47778
ISSN: 1300-0144
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection

Files in This Item:
File SizeFormat 
turkjmedsci-51-231.pdf131.14 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

72
checked on Aug 24, 2024

Download(s)

26
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.